
Cerus Corporation CERS
$ 2.61
0.38%
Cerus Corporation Shares | CERS
Annual Shares Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 191 M | 185 M | 180 M | 177 M | 171 M | 164 M | 140 M | 132 M | 108 M | 102 M | 96.1 M | 74.8 M | 67.6 M | 54.5 M | 48 M | 40.3 M | 34.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 191 M | 34.8 M | 116 M |
Quarterly Shares Cerus Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 201 M | 194 M | 192 M | 191 M | 187 M | 185 M | 185 M | 182 M | 181 M | 181 M | 178 M | - | 177 M | 177 M | 174 M | 174 M | 172 M | 171 M | 169 M | 168 M | 167 M | 164 M | 157 M | 144 M | 141 M | 138 M | 137 M | 137 M | 134 M | 131 M | 125 M | 116 M | 110 M | 105 M | 104 M | 103 M | 103 M | 102 M | 99.5 M | 99.1 M | 96.9 M | 95.7 M | 93.4 M | 80.4 M | 75.2 M | 72.9 M | 72.1 M | 71.9 M | 69.8 M | 69.7 M | 59.7 M | 56.3 M | 54.9 M | 54.4 M | 53.1 M | 51.2 M | 47.7 M | 47.6 M | 47.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 201 M | 47.4 M | 125 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AnaptysBio
ANAB
|
29 M | $ 51.7 | 1.83 % | $ 1.5 B | ||
|
Allakos
ALLK
|
88.8 M | - | - | $ 28.6 M | ||
|
Bicycle Therapeutics plc
BCYC
|
69.3 M | $ 3.73 | 3.61 % | $ 258 M | ||
|
Black Diamond Therapeutics
BDTX
|
56.9 M | $ 1.89 | 0.53 % | $ 107 M | ||
|
Clovis Oncology
CLVS
|
128 M | - | -7.23 % | $ 13 M | ||
|
Concert Pharmaceuticals
CNCE
|
34.4 M | - | - | $ 401 M | ||
|
Rezolute
RZLT
|
104 M | $ 3.94 | 1.87 % | $ 299 M | ||
|
Evelo Biosciences
EVLO
|
87.2 M | - | -14.46 % | $ 27.9 M | ||
|
BioLineRx Ltd.
BLRX
|
2.47 B | $ 2.52 | 1.17 % | $ 6.21 B | ||
|
BioMarin Pharmaceutical
BMRN
|
192 M | $ 61.35 | 0.06 % | $ 11.8 B | ||
|
Benitec Biopharma
BNTC
|
46.6 M | $ 9.64 | 0.46 % | $ 449 M | ||
|
BioNTech SE
BNTX
|
242 M | $ 99.26 | 0.81 % | $ 24 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
59.3 M | - | - | $ 384 M | ||
|
Genocea Biosciences
GNCA
|
68.6 M | - | -15.0 % | $ 3.04 M | ||
|
Burford Capital Limited
BUR
|
219 M | $ 3.63 | 3.93 % | $ 795 M | ||
|
Amryt Pharma plc
AMYT
|
236 M | - | - | $ 621 M | ||
|
G1 Therapeutics
GTHX
|
51.7 M | - | - | $ 370 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.17 | 0.46 % | $ 3.57 M | ||
|
Catalyst Biosciences
CBIO
|
89.3 M | $ 14.24 | 0.35 % | $ 1.27 B | ||
|
C4 Therapeutics
CCCC
|
82.9 M | $ 3.03 | 0.3 % | $ 251 M | ||
|
Codexis
CDXS
|
87.1 M | $ 1.37 | 1.45 % | $ 119 M | ||
|
AbbVie
ABBV
|
1.77 B | $ 265.12 | 0.09 % | $ 469 B | ||
|
Humanigen
HGEN
|
89.2 M | - | -81.12 % | $ 4.28 M | ||
|
Coherus BioSciences
CHRS
|
117 M | $ 1.17 | 1.48 % | $ 137 M | ||
|
AbCellera Biologics
ABCL
|
299 M | $ 12.65 | 2.76 % | $ 3.78 B | ||
|
Abeona Therapeutics
ABEO
|
53 M | $ 5.43 | 2.65 % | $ 288 M | ||
|
Celldex Therapeutics
CLDX
|
66.4 M | $ 31.48 | 1.16 % | $ 2.09 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
12.2 M | $ 4.12 | 1.98 % | $ 50.3 M | ||
|
Фармсинтез
LIFE
|
301 M | - | - | - | ||
|
Cellectar Biosciences
CLRB
|
2.61 M | $ 2.08 | 0.48 % | $ 5.43 M | ||
|
IGM Biosciences
IGMS
|
60.5 M | - | - | $ 76.9 M | ||
|
IMV
IMV
|
8.34 M | - | - | $ 13.1 M | ||
|
Kinnate Biopharma
KNTE
|
46.6 M | - | - | $ 123 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | ||
|
Karuna Therapeutics
KRTX
|
37 M | - | - | $ 12.2 B | ||
|
Cocrystal Pharma
COCP
|
11.3 M | $ 1.15 | 1.67 % | $ 13 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
94.1 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Collegium Pharmaceutical
COLL
|
31.7 M | $ 22.64 | 0.85 % | $ 717 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
104 M | $ 118.51 | 4.93 % | $ 12.3 B | ||
|
Chimerix
CMRX
|
89.7 M | - | - | $ 756 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
13.3 M | $ 7.45 | 0.19 % | $ 99.2 M | ||
|
Curis
CRIS
|
13.2 M | $ 0.88 | 0.85 % | $ 11.6 M | ||
|
CorMedix
CRMD
|
72 K | $ 7.77 | 1.04 % | $ 560 K | ||
|
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 55.7 | 0.23 % | $ 5.01 B | ||
|
Corvus Pharmaceuticals
CRVS
|
79 M | $ 11.8 | 8.21 % | $ 932 M | ||
|
Champions Oncology
CSBR
|
13.8 M | $ 4.95 | 0.38 % | $ 68.5 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.88 | 0.62 % | $ 935 M | ||
|
Cue Biopharma
CUE
|
94.7 M | $ 32.85 | 3.6 % | $ 3.11 B | ||
|
CEL-SCI Corporation
CVM
|
8.02 M | $ 1.72 | 2.38 % | $ 13.8 M |